SCHEMBL6894370

SCHEMBL6894370

N#Cc1c(N2CCSCC2)nc2c(-c3cnc4ccccc4c3)cnn2c1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
HPGD P15428 4/20 0.40
KDM4E B2RXH2 3/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
RXFP1 Q9HBX9 2/20 0.36
NPC1 O15118 4/20 0.35
CASP3 P42574 2/20 0.35
SENP8 Q96LD8 2/20 0.35
SENP7 Q9BQF6 2/20 0.35
SENP6 Q9GZR1 2/20 0.35
ADORA2A P29274 3/20 0.34
ADRA2A P08913 1/20 0.34
RAB9A P51151 4/20 0.34
CHEK1 O14757 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CCNA1 P78396 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL585053 0.89 ADORA2A (0.45) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL7886529 0.88 NPC1 (0.37) ALDH1A1HPGDKDM4ETSHRHSD17B10
SCHEMBL6891730 0.87 AKT1 (0.35) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL7883380 0.87 MEN1 (0.36) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL7879265 0.86 NPC1 (0.36) ALDH1A1HPGDKDM4ETSHRHSD17B10
SCHEMBL6893394 0.86 CHEK1 (0.37) ALDH1A1HPGDKDM4ETSHRHSD17B10
SCHEMBL6894351 0.84 PARP10 (0.37) MEN1KMT2ANPC1CASP3SENP8
SCHEMBL10238735 0.83 CHEK1 (0.46) MEN1KMT2ANPC1CASP3SENP8
SCHEMBL6893362 0.79 BRD4 (0.34) MEN1KMT2ANPC1CASP3SENP8
SCHEMBL6893367 0.79 PIK3CA (0.36) ALDH1A1HPGDKDM4EHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 ALDH1A1 1242/4885HPGD 52/4885KDM4E 3091/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR ALDH1A1 3479/4885HPGD 2087/4885KDM4E 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.